With China set to become a major hub of biotech innovation, Lonza CEO Marc Funk says the CDMO will take a pragmatic approach to expanding its position from “timid actor” to major player in the region. When Marc Funk became CEO of Lonza in March 2019, he had two immediate objectives. The first was to carve out the contract development and manufacturing organization’s (CDMO) Specialty Ingredients segment (LSI) and the second was for the firm to be recognized more of…